Kornimate/medical-research-clean huggingface dataset:
isolation of volatile organic compounds (vocs) related to the olfactory signature of breast cancer

Conditions: Breast Cancer; Surgery

Summary: to ascertain the possibilities to isolate the breast cancer olfactive signature.

patient recruitment during the first surgery consultation in curie institute. odor sampling (non-invasive) with an odor-sensing polymer (sorbstar® polymer developed especially for the trace level analysis), on: * the hands, before and after surgical excision of the tumor (friction of the hands) * the diseased breast, before and after surgical excision of the tumor (via a compress positioned on the breast for 1 night) * the tumor, during the surgical procedure (odor collection over a tumor sample). each patient will be her own witness, before and after surgical excision, in an attempt to isolate the chemical signature tracks of breast cancer. the samples after surgery will be made after healing and before implementation of a treatment (chemotherapy and / or radiotherapy).

Eligibility criteria:
inclusion criteria: 1. patient received in surgery consultation for an invasive non metastatic breast cancer treated by breast-conserving surgery with axillary or sentinel node dissection 2. of-age female patient (over 18 years old) 3. life expectancy \> to 1 year at the inclusion 4. performance status: 0 or 1 or 2 5. patient benefiting from the social security 6. signature informed consent of the study exclusion criteria: 1. neoplasia in progress or neoplasia history of cancer other than breast to be treated. 2. wound presence on breasts 3. male subjects 4. specified metastatic breast cancer 5. concomitant medication taken one month before the surgical act (antibiotics, corticoids, anti-diabetics) 6. persons under guardianship or deprived of liberty 7. impossibility to submit to the medical monitoring expected by the study for geographical, social or psychological reasons.

Keywords: breast volatile organic compounds
effects of alcohol history on effects of nitrous oxide - 9

Conditions: Alcohol-Related Disorders; Opioid-Related Disorders; Substance-Related Disorders

Summary: the purpose of this study is to conduct experiments to examine subjective and reinforcing effects of nitrous oxide. mood altering and psychomotor effects will be tested on non-drug abusers and preference procedures will be used to assess reinforcing effects. comparisons between nitrous oxide, opiates, and benzodiazepine antagonists will be made. to determine effects of alcohol history on the reinforcing, subjective and psychomotor effects of nitrous oxide in healthy volunteers.


Eligibility criteria:
please contact site for information.

Keywords: nitrous oxide subjective effects ethanol healthy volunteer
the interaction of body composition, sex hormones and exercise in men

Conditions: Normal-weight Obesity

Summary: the overall objective of this project is to advance understanding of the causes of normal weight obesity (nwo) in men, namely the hormone profile and related potential mediating mechanisms, and the efficacy of different modes of exercise to restore body composition and cardiometabolic health in this population.


Eligibility criteria:
inclusion criteria: * biological male * bmi 18.5 - 24.9 kg/m2 or \>/= 30 kg/m2 * body fat \ /= 25% * ability and willingness to engage in an exercise training regimen exclusion criteria: * presence of a chronic health condition, or regular use of associate prescribed medications, that would substantially impact study variables * excessive alcohol use or use of tobacco products, vape products, or illicit drugs * presence of an electrical implant, such as a pacemaker

Keywords: body composition sex hormones exercise metabolic health
manual rotation in persistent occiput posterior position

Conditions: Manual Rotation of A Liveborn

Summary: is part of routine obstetric care to attempt a manual rotation in all fetus that are in a persistent op at delivery. nevertheless, little is known about the success of this intervention or about the relation of some ultrasound measures with the outcome.

persistent op at delivery occurs in approximately 10% of fetuses and studies have shown an increase in short-term and long-term maternal and fetal complications such as prolonged labour, maternal exhaustion, fetal distress, instrumental delivery, caesarean delivery and severe perineal tears. manual rotation of the fetal occiput to oa position has been described as a safe and effective intervention in the setting of labour arrest but evidence is limited. therefore, the investigators aim to evaluate: 1. the success of manual rotation of the fetal occiput in op in 2nd stage of labour; the relation of progression angle (pa) accessed by ultrasound and the success of manual rotation; this is as prospective study with a sample size calculated of 50 participants. 1. º identify an op position during digital examination in the first evaluation at full cervical dilatation (t=0) 2. º get informed consent from the pregnant woman. 3. º wait for the first urge to push or t=30 m (multiparous) or t=60 (nulliparous) 4. º confirm fetal head position by ultrasound and measure pa. 5. º attempt a manual rotation to anterior position accordingly to the protocol. 6. º confirm fetal head position by ultrasound.

Eligibility criteria:
inclusion criteria: * singleton pregnancies * \>37 weeks of pregnancy * fetus in cephalic presentation * fetal weight estimation p10-90 * fetal head in a posterior position in the moment of full cervical dilatation. exclusion criteria: - do not give or do not be able to give written consent
clemastine treatment in individuals with williams syndrome

Conditions: Williams Syndrome

Summary: this study explores the neurobiological etiology of williams syndrome and potential therapeutic targets for associated social, motor, and cognitive abnormalities. the main translational objective will be to test the effectiveness of clemasntine on neurocognitive and other associated abnormalities in individuals with williams syndrome.

the overarching aim of the research proposed is to examine the safty of clemastine use for individuals with williams syndrome. further, we wish to examine the relationship between clemastine treatment and cognitive, motor and behavioral deficits in individuals with williams syndrome. this study is an open-label study with a blinded randomize withdrawal. each participant will go through a baseline evaluation (see study outcomes) and will be treated with the fda approved drug clemastine, in an age dependent dose (dosage table below). after a substantial improvement will be noticed, the participants will be divided into 2 groups, in a randomized, double-blind, placebo-control study design.

Eligibility criteria:
inclusion criteria: * individuals with williams syndrome, which has been confirmed by genetic testing. * ages 6-30. * normal values in safety variables (e.g. normal ecg 120-129/80-84). * no change in psychotropic medications and dosage during the last 4 weeks. * during the study, no pharmacological change that may impact the study (e.g. adhd * medications). exclusion criteria: * individuals with another genetic disorder besides williams syndrome. * individuals with williams syndrome, younger than 6 or older than 30 years old. * significant change in normal values in safety variables (e.g. high or low ecg). * change in medications and dosage during the last 4 weeks prior the beginning and * during the study. * pregnancy. * using addictive substances such as alcohol.

Keywords: clemastine cognition myelination abnormalities
somatostatin receptor pet/ct in sstr-related disease patients

Conditions: SSTR-related Disease; Tumor; Positron Emission Tomography; Metastasis

Summary: to evaluate the potential usefulness of 68ga/18f-tate/jr11/lm3 positron emission tomography/computed tomography (pet/ct) for the diagnosis of primary and metastatic lesions in various sstr-related disease patients.

subjects with various sstr-related disease patients underwent 68ga/18f-tate/jr11/ lm3 pet/ct either for an initial assessment or for recurrence detection. lesions uptake was quantified by the maximum standard uptake value (suvmax). the sensitivity, specificity, positive predictive value (ppv), negative predictive value (npv) and accuracy of 68ga/18f-tate/jr11/lm3 pet/ct were calculated.

Eligibility criteria:
inclusion criteria: - (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated malignant tumors (supporting evidence may include mri, ct, tumor markers and pathology report); (iii) patients who had scheduled sstr pet/ct scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the clinical research ethics committee. exclusion criteria: - (i) patients with non-malignant lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Keywords: pet/ct sstr angonist antagonist
patient performance on virtual reality visual field devices as compared to standard of care

Conditions: Glaucoma

Summary: the purpose of this research is to study the effectiveness and patient experience when measuring visual fields using virtual reality goggles.


Eligibility criteria:
inclusion: * any individual who is physically able to take a virtual reality visual field test * patients who either have glaucoma, are glaucoma suspects, or have a strong family history of glaucoma, or have other visual field defects, and normal individual * age: individuals who are old enough to comprehend the instructions and procedures (1-90) exclusion: * adults unable to consent, prisoners * participants who are too tired to take a visual field test * participants who refuse to consent * individuals who are functionally unable to use vrvf

Keywords: visual field virtual reality
contrast-enhanced ultrasound as a screening tool for kidney cancer in patients with von-hippel lindau

Conditions: Von-Hippel Lindau; Kidney Disease, Chronic

Summary: the purpose of this study is to determine if contrast-enhanced ultrasound can detect abnormal features of kidney lesions in patients with von-hippel lindau with the same accuracy as conventional ultrasound and contrast-enhanced magnetic resonance imaging (mri)

this is a pilot cross-sectional study that compares contrast enhanced ultrasound to conventional ultrasound and contrasted mri. any patient undergoing annual imaging screening is eligible, but the investigators will target inclusion of at least 10 subjects who have at least 1 kidney lesion. therefore, up to 5 subjects may have no current kidney lesions. subject participation will be only for the day of ceus study. there will be no follow-up period for this study. however, if results are encouraging, a longitudinal observational study may follow, and these same subjects would be eligible for enrollment. eligible subjects will undergo a contrast enhanced ultrasound. following completion of imaging, all ceus, mri (within 4 months) and b-mode (at time of ceus) us studies will be de-identified. blinded radiologists will interpret images and provide an overall assessment of risk of malignancy to each kidney using the bosniak criteria for each kidney lesion present. the bosniak criteria places cystic lesions into one of 5 categories (i, ii, iif, iii and iv) based on lesion characteristics. ceus based diagnosis will be compared to the diagnoses on routine b-mode us and contrast-enhanced mri.

Eligibility criteria:
inclusion criteria: to be eligible for the present study, patients must meet the following criteria: 1. able to provide written informed consent 2. willing to comply with protocol requirements 3. at least 16 years of age 4. carry a diagnosis of vhl and able to undergo routine clinical screening tests for rcc exclusion criteria: 1. critically ill or medically unstable or in an intensive care setting and whose critical course during the observation period would be unpredictable 2. known hypersensitivity to sulfur hexafluoride or to any component of perflutren lipid (definity®) or sulfur hexafluoride (lumason®) 3. right to left shunt, severe pulmonary hypertension (pulmonary artery pressure \>90mmhg), or adult respiratory distress syndrome 4. active cardiac disease including any of the following: a. severe congestive heart failure (class iv in accordance with the classification of the new york heart association) b.unstable angina. c.symptomatic arrhythmia (i.e. tachycardia, bradycardia, supraventricular tachycardia, ventricular fibrillation, ventricular tachycardia, atrial flutter or fibrillation). d.myocardial infarction within 14 days prior to the date of proposed microbubble administration. 5. has any other medical condition or other circumstances that would significantly decrease the chances of obtaining reliable data or of achieving the study objectives such as: * mental illness * drug abuse 6. female patient who is pregnant or lactating 7. obesity that limits obtainment of acceptable images
wal 801 cl dry syrup in paediatric atopic dermatitis patients

Conditions: Dermatitis, Atopic

Summary: study to investigate the safety and efficacy of wal 801 cl dry syrup on pruritus associated with paediatric atopic dermatitis in comparison with that of ketotifen fumarate dry syrup and to confirm the appropriateness of dosage of wal801 dry syrup.


Eligibility criteria:
inclusion criteria: for inclusion in this study, patients must be pediatric atopic dermatitis patients that meet the following criteria and thus be appropriate for observation of pruritus. diagnosis of atopic dermatitis was conducted in accordance with the "definition and diagnostic criteria of atopic dermatitis" issued by the japanese dermatological association. * 15 years of age or younger * body weight of 14 kg or more * outpatients * one week or longer has passed since the patient started to use an external steroid preparation at "strong" or lower grade, or stopped using any external steroid preparation, at the time of obtainment of consent from the patient * pruritus with "2" or higher grade, immediately before initial administration exclusion criteria: * use of sustained release adrenocorticotropic hormone (kenacort® a, depo-medrol®, etc.), oral preparation of methotrexate, or oral preparation of ciclosporin, within 4 weeks before initial administration of the investigational product * oral intake, inhalation and injection of any steroid within 2 weeks before initial administration of the investigational product * use of any external steroid preparation at "very strong" or higher grade in any sites other than the face or scalp within 2 weeks before initial administration of the investigational product * undergoing phototherapy * undergoing specific desensitization therapy or modulation therapy * past history of contact dermatitis caused by external steroid preparation * possibility of exacerbation by an external steroid preparation of infectious skin disease caused by bacteria, fungi, or virus * present and past history of convulsive disorder, such as epilepsy (convulsion threshold values may be lowered by the reference drug, ketotifen fumarate) * clinically significant hepatic, renal, or cardiac disease or other complications: therefore, judgement that the patient is ineligible for inclusion in this study (please note that patients must be excluded from the study if the patients fell under grade 2 or more, in the mhw (ministry of health and welfare) adverse reaction severity classification criteria.) * past history of allergy to any drug * participation in any other clinical study, or history of participation in any other clinical study within 6 months before the date when the patient gave consent to participate in this study * judgement by the principal investigator or investigator that the patient is ineligible for inclusion in this study
validity reliability of the dubousset functional test in parkinson disease

Conditions: Parkinson Disease; Balance; Distorted; Fall; Gait Disorders, Neurologic

Summary: in order to achieve collaborative patient-centered rehabilitation in parkinson's disease, detailed evaluation of walking and balance in evaluating the perceived difficulty in daily life is important to evaluate the progression of the disease and its response to treatments. in the literature, there are many scales that evaluate balance and functional performance in parkinson disease. however there is no validity and reliability study of dubousset function test developed to evaluate balance and functional performance of parkinson disease. for this reason, the aim of study is to examine the validity and reliability of dubousset function test in parkinson disease.

balance disorders are very common in patients with parkinson's, and these disorders significantly affect the patient's body alignment and participation. especially during walking, balance disorders occur, resulting in falls, disability and injury in the advanced stage of the disease. as a result of these losses in patients, falls can be seen, and the severity of disability that increases with age affects the quality of life of individuals by affecting their living in their own homes. dubousset functional test (dft); a conceptually practical four-component assessment test has been proposed by dr. jean dubousset to assess the functional capacity of adult individuals. the validity of the test was made in individuals with spinal deformity. dft; it consists of four components: getting up from a chair without arms and walking 5 meters forward and backward, descending and climbing steps, transition from standing to sitting on the ground, and the dual task test in which the individual walks while counting down from 50 at the same time in the literature, there are many scales that evaluate balance and functional performance in parkinson disease. however there is no validity and reliability study of dubousset function test developed to evaluate balance and functional performance of parkinson disease. for this reason, the aim of study is to examine the validity and reliability of dubousset function test in parkinson disease.

Eligibility criteria:
inclusion criteria: being diagnosed with parkinson's disease (hoehn yahr level (1-3) * volunteering to participate in research and approving the informed consent form being over the age of 40 * using stable parkinson's disease medication for at least 4 weeks * no cooperation and communication problems exclusion criteria: * • individuals with any other neurological and orthopedic problems uncontrollable hypertension to your serious disk significant comorbidity affecting balance and gait * those with cooperation and communication problems
neuroendocrine neoplasms methylation based classifier - the nemesis-study

Conditions: Neuroendocrine Tumors

Summary: neuroendocrine neoplasms (nen) are rare tumors that mainly occur in the gastrointestinal tract and the lungs. the currently available diagnostic and prognostic markers do not adequately represent the diversity of these tumors. methylation analyzes of the tumor dna represent a new, promising approach. the aim of this project is therefore to improve the diagnostic and prognostic evaluation of neuroendocrine neoplasms by means of methylation analysis of the tumor dna. on the one hand, existing tumor samples from the biobank of basel university hospital are evaluated, on the other hand, patients who are undergoing an operation will be prospectively inquired


Eligibility criteria:
inclusion criteria: * neuroendocrine tumor exclusion criteria: * insufficient amount or quality of neuroendocrine tumor sample

Keywords: methyloma
probenecid as medication for alcohol use disorder (prob)

Conditions: Alcohol Use Disorder

Summary: the design is a randomized, within-subject, crossover, double-blind, placebo-controlled human alcohol laboratory study with one oral dose of 2g probenecid or placebo administered in two laboratory sessions.

there will be a total of four study visits. visit 1 is the screening for eligibility (medical and physical examination). on visits 2 and 3, participants will undergo an alcohol laboratory session with a one week washout period before administering the alternate therapy. the study will conclude at visit 4.

Eligibility criteria:
inclusion criteria: * male or female, 21-70 (inclusive) years; women \>7 drinks/week; men \>14 drinks/week; * meet any dsm-5 criteria score for aud; * breath alcohol content (brac)=0.00 at each visit; * in good health as confirmed by medical history, physical examination and lab tests; * willing to adhere to the study procedures; * understand informed consent and questionnaires in english at an 8th grade level exclusion criteria: * women who are breastfeeding or have a positive urine screen for pregnancy * crcl \< 60ml/min * taking aspirin (salicylates may reduce effect of probenecid) * taking penicillin * taking methotrexate (may increase concentration) * taking other medications that may interact with probenecid * history of suicide attempts in the last three years * current diagnosis of another substance disorder(s) other than nicotine, as assessed by self-reports and urine toxicology screen at baseline * history of hypersensitivity to sulfa drugs
diets, lipoproteins and inflammation markers

Conditions: Cardiovascular Diseases; Metabolic Syndrome; Diet, Healthy; Vegan Diet; Inflammatory Response

Summary: systematic inflammation and lipid profiles are two major therapeutic targets for cardiovascular diseases. the effectiveness of vegan diet has been reported (doi: 10.3389/fnut.2022.807810). aim: to compare the effectiveness of a nutritionally balanced vegan diet and a myplate diet ((taiwanese version) on systematic inflammation and lipoprotein subclass. design: randomized crossover design


Eligibility criteria:
inclusion criteria: patients with dyslipidemia (at least one of the following) * tg ≥ 150 mg/dl * tc ≥ 200 mg/dl * ldl-c≥ 130 mg/dl, * hdl-c \< 45 mg/dl for male or \< 55 mg/dl for female or receiving statin treatment exclusion criteria (fulfill one of the following condition): * chronic kidney disease * history of coronary artery disease * ischemic heart disease, * heart failure, * stroke, * cancer of any type
safety and efficacy of human umbilical cord blood plasma infusion for age-related cognitive decline

Conditions: Age-related Cognitive Decline

Summary: this study is designed to investigate the safety of umbilical cord blood plasma infusions in elderly adults regardless of gender, with age-related cognitive decline. human clinical data of the use of young plasma appear to show beneficial cognitive effects.


Eligibility criteria:
inclusion criteria: 1. age 65-85 years old 2. evidence of cognitive decline on neuro-cognitive testing 3. able to participate in research trial for 12 months 4. women must have documented menopause or infertility determination 5. ability to receive intravenous infusions 6. patient or legally authorized representative able to sign informed consent exclusion criteria: 1. patients receiving any other investigational biologics or drugs 2. history of transfusion reaction 3. dementia related to specific pathology (alzheimer's disease, alcohol-related, etc.) 4. inability to participate in cognitive or performance testing 5. history of cancer in the last 5 years 6. history of infectious disease within the previous 12 months 7. severe kidney (egfr\< 30) and heart failure (class iii/iv) 8. history of human immunodeficiency virus infection 9. history of hepatitis b, or c 10. history of immunosuppressive therapy 11. history of organ transplantation 12. difficulty of obtaining peripheral venous access 13. allergy to histamine blockers 14. inability to participate in the clinical trial at any data collection and end points -